Effectiveness of low-dose pentoxithylline combined with tocopherol acetate in intrathoracic sacroidosis
https://doi.org/10.18093/0869-0189-2005-0-1-24-28
Abstract
We conducted a simple prospective trial studied influence of pentoxifylline on the course of active pulmonary sarcoidosis in 70 patients. This drug decreasing TNF-α (tissue necrosis factor-α) level was given orally in the dose of 600 mg 3 times a day in combination with α-to copherol in the dose of 400 IU twice a day. Fourteen patients stopped treatment because of side effects (nausea, dizziness). Fifty-six patients had clinical improvement in 71.4 % of cases, reduction of intrathoracic lymphadenopathy in 71.8 %, reliable improvement in DLCO (lung diffusing capacity for carbon monoxide) and increase in the blood lymphocyte count. The clinical effectiveness of this drug combination was less in chronic sarcoidosis and in patients who had taken systemic glucocorticosteroids or antituberculotics before. A multicentral comparative trial is required to include pentoxifylline to guidelines on management sarcoidosis patients.
About the Authors
A. A. Vizel
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
E. A. Vizel
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
G. R. Nasretdinova
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
L. V. Islamova
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
O. G. Kataev
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
F. A. Mingaleev
Кафедра фтизиопульмонологии Казанского медицинского университета МЗ РФ; Межрегиональный клинико-диагностический центр
Russian Federation
Russian Federation
References
1. ATS/ERS/WASOG statement on sarcoidosis. Eur. Respir. J. 1999; 14 (4): 735—737.
2. Morell F., Levy G., Orriols R. et al. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest 2002; 121 (4): 1239—1244.
3. Ziegenhagen M.W., Rothe M.E., Zissel G., Muller-Quernheim J. Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidos. Vasc. Diffuse Lung Dis. 2002; 19 (3): 185—190.
4. Moller D.R. Treatment of sarcoidosis — from a basic science point of view. J. Intern. Med. 2003; 253 (1): 31-40.
5. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am. J. Respir. Med. 2003; 2 (4): 311—320.
6. Nasretdinova G.R., Vizel A.A., Gouryleva M.E., Amirov N.B. Pentoxifylline in treatment of pulmonary sarcoidosis. Eur. Resp. J. 2002; 20 (suppl. 38): 433s, ref. 2749.
7. Baradzina H.L., Katovich I.L., Tahanovich A.D. et al. TNF-α release suppression by pentoxifylline in sarcoidosis.Eur. Respir. J. 2003; 22 (suppl. 40): 105s, ref. P731.
8. Baughman R.P., Ohmichi M., Lower E.E. Combination therapy for sarcoidosis. Sarcoidos. Vasc. Diffuse Lung Dis. 2001; 18 (2): 133—137.
Review
For citations:
Vizel A.A., Vizel E.A., Nasretdinova G.R., Islamova L.V., Kataev O.G., Mingaleev F.A. Effectiveness of low-dose pentoxithylline combined with tocopherol acetate in intrathoracic sacroidosis. PULMONOLOGIYA. 2005;(1):24-28. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-1-24-28
Views:
2091
Email this article 